Presentation by Shawn Li, Merck: Transition of Multi-Attribute Method (MAM) to GMP for biotherapeutics
Presentation by Shawn Li, Merck: Transition of Multi-Attribute Method (MAM) to GMP for biotherapeutics
Loading view.
Presentation by Yuting Huang, Pfizer: Accelerating Biotherapeutic Development by Automated MAM
Presentation by Yuting Huang, Pfizer: Accelerating Biotherapeutic Development by Automated MAM
Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
USP Biologics Open Forum on MAM
USP Biologics Open Forum on MAM
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the benefits of New Peak Detection
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the…
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes
Presentation by Adam Evans, Janssen: Multi-Attribute Monitoring from Development to Commercial QC
Presentation by Adam Evans, Janssen: Multi-Attribute Monitoring from Development to Commercial QC
Presentation by Diane McCarthy, US Pharmacopeia: USP Standards to Support Multi-Attribute Methods
Presentation by Diane McCarthy, US Pharmacopeia: USP Standards to Support Multi-Attribute Methods
Presentation by John Schiel, NIST, Mass Spectrometry as a Disruptive Technology for Emerging Modalities
Presentation by John Schiel, NIST, Mass Spectrometry as a Disruptive Technology for Emerging Modalities